This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

The New Abbott Labs Is Leaner, but Needs Better Execution

So Abbott's devices struggle, while disappointing in its own right, doesn't necessarily reflect poor execution as much as it appears to be a marketplace trend. Plus, given that the company is now only one quarter removed from the AbbVie spin-off, management deserves more time to get this situation corrected. It didn't impact profitability much because Abbott was able to beat consensus EPS estimates, which also arrived 2 cents higher year over year -- excluding AbbVie.

Diversification Still an Issue

Aside from the weakness in the devices business, Abbott no longer appears as diversified as it should following the AbbVie spin-off. It's certainly impressive that the nutritional business is performing so well, growing at 9% both on a reported and operational basis. However, this means that nutrition now accounts for almost 32% of Abbott's total revenue.


The nutrition business can be expected to keep performing well, but this is where better diversification or an improved devices business would alleviate concerns. Investors are encouraged to show some patience here; another quarter or two of underperformance in devices should raise the threat level.

Management, however, seems confident about Abbott's future prospects -- guiding full-year earnings per share to between $1.98 to $2.04, up from $1.74 last year, with second-quarter EPS expected to be between 43 cents and 45 cents -- in line with Street estimates on mid-single-digit revenue growth.

Bottom Line

There are several areas that Abbott's management need to address. However, the stock, which is trading at a P/E of 11, or half that of J&J's, presumes that these obstacles are too much to overcome. Although the stock appears cheap on these metrics, shares are not as attractive based on fiscal 2014 estimates, which pushes the P/E closer to 16. I'm confident that management will execute in the right direction, but logic would suggest that investors stay away until there's more evidence they have things under control.

At the time of publication, the author had no position in any of the stocks mentioned.


This article was written by an independent contributor, separate from TheStreet's regular news coverage.

Richard Saintvilus is a private investor with an information technology and engineering background and the founder and producer of the investor Web site Saint's Sense. He has been investing and trading for over 15 years. He employs conservative strategies in assessing equities and appraising value while minimizing downside risk. His decisions are based in part on management, growth prospects, return on equity and price-to-earnings as well as macroeconomic factors. He is an investor who seeks opportunities whether on the long or short side and believes in changing positions as information changes.
2 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,131.97 +100.83 0.59%
S&P 500 1,998.98 +14.85 0.75%
NASDAQ 4,552.7590 +33.8570 0.75%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs